Moderna Inc (MRNA) USD0.0001
- Add to watchlist
- This stock can be held in a
Share news, reports & tips
-
US close: Stocks rise amid Nvidia-led tech rally
22 February 2024 22:23
(Sharecast News) - Wall Street saw a surge in stock performances on Thursday, buoyed by robust earnings reports from chipmaker Nvidia and positive data trends.
-
Moderna posts surprise profit, shares spark
22 February 2024 11:49
(Sharecast News) - Moderna posted a surprise quarterly profit on Thursday, despite sales of its Covid vaccine continuing to slide.
-
Moderna shares surge on cancer trial combo with Merck treatment
14 December 2023 12:13
(Sharecast News) - Shares in Moderna surged on Thursday after trial results of its experimental cancer vaccine, used in conjunction with Merck's Keytruda treatment, reduced the risk of death or relapse...
-
US close: Stocks rise as Dow snaps three-day losing streak
4 October 2023 23:00
(Sharecast News) - Wall Street ended with a rebound on Wednesday, with major US stock indices ending the day in positive territory following a streak of losses, triggered partially by alleviating bond yields...
-
Updated Covid vaccine effective against new strain - Moderna
6 September 2023 13:24
(Sharecast News) - Moderna's updated Covid-19 vaccine has shown to be effective against a potentially dangerous new variant, the US biotech said on Wednesday.
-
Moderna posts surprise first-quarter profit
4 May 2023 12:45
(Sharecast News) - Moderna reported above-forecast first-quarter numbers on Thursday, despite demand for its Covid-19 vaccine continuing to wane.
-
Moderna Covid vaccine sales top $18bn
9 January 2023 12:18
(Sharecast News) - US biotech Moderna said on Monday that it sold more than $18bn of Covid-19 vaccines last year.
-
Moderna Q3 earnings and sales disappoint
3 November 2022 11:57
(Sharecast News) - Biotechnology outfit Moderna missed analysts' estimates for third quarter earnings and sales by a wide margin.
-
Covid-19 cases surge during latest week due to BA.4 and BA.5 Covid-19 sub-variants
1 July 2022 13:22
(Sharecast News) - The number of new coronavirus cases in Britain jumped again during the preceding week, likely due to the more infectious BA.4 and BA.5 variants of the Omicron variant of Covid-19.
-
Moderna boosts Covid-19 vaccine sales forecast
24 March 2022 09:26
(Sharecast News) - Moderna has boosted its 2022 sales forecast for its Covid-19 vaccine to $21bn, the US biotech confirmed on Thursday.
-
Immune system creates neutralising antibodies against Omicron after three exposures
7 February 2022 15:26
(Sharecast News) - German scientists have shown that the human immune system creates an abundant amount of high quality antibodies capable of neutralising Omicron once it has encountered the virus's...
-
Novavax Covid vaccine approved for use in the UK
3 February 2022 14:06
(Sharecast News) - The UK has approved Novavax's Covid-19 vaccine for use in adults, the medicines regulator confirmed on Thursday.
Company announcements Announcements
No company announcements about Moderna Inc USD0.0001 were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.